| pubmed-article:8683378 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8683378 | lifeskim:mentions | umls-concept:C1335749 | lld:lifeskim |
| pubmed-article:8683378 | lifeskim:mentions | umls-concept:C1709900 | lld:lifeskim |
| pubmed-article:8683378 | lifeskim:mentions | umls-concept:C0597712 | lld:lifeskim |
| pubmed-article:8683378 | lifeskim:mentions | umls-concept:C1511790 | lld:lifeskim |
| pubmed-article:8683378 | lifeskim:mentions | umls-concept:C0334044 | lld:lifeskim |
| pubmed-article:8683378 | lifeskim:mentions | umls-concept:C0079419 | lld:lifeskim |
| pubmed-article:8683378 | lifeskim:mentions | umls-concept:C0332257 | lld:lifeskim |
| pubmed-article:8683378 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8683378 | pubmed:dateCreated | 1996-8-19 | lld:pubmed |
| pubmed-article:8683378 | pubmed:abstractText | Ninety-four patients with transitional cell carcinoma (TCC) of the renal pelvis and ureter, including dysplastic lesions, were studied for p53 and bcl-2 protein expression by immunohistochemistry. Twenty-one patients were also studied for p53 gene mutations by direct sequencing and for bcl-2 gene rearrangement by Southern blot analysis. Overexpressed p53 protein was detected in 26 cases (27.7 per cent). bcl-2 immunostaining was observed in 21 tumours (22.3 per cent), including four cases with labelling for p53. Furthermore, the dysplastic lesions surrounding 19 p53-positive tumours also stained for p53. bcl-2 expression was also detected frequently in dysplastic lesions adjacent to 14 bcl-2-positive TCCs. Positive reactions of dysplastic lesions were also found adjacent to 37 bcl-2-negative tumours. p53 point mutation was detected in 6 of 21 cases. Five of the six cases were positive for p53 protein. blc-2 positivity was detected in 3 of 21 tumours, without bcl-2 gene rearrangements in the major breakpoint region. Overexpressed p53 protein was frequently detected in both high-grade (P < 0.05) and invasive tumours (P < 0.05). In three cases of p53-positive non-papillary invasive tumours, bcl-2 was found in non-invasive portions, but was not present in invasive areas. These findings suggest that overexpression (mutation) of p53 and/or bcl-2 protein may be early events in tumourigenesis and that p53 alterations in particular are essential for the maintenance of a malignant phenotype in tumour development. | lld:pubmed |
| pubmed-article:8683378 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8683378 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8683378 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8683378 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8683378 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8683378 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8683378 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8683378 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8683378 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8683378 | pubmed:issn | 0022-3417 | lld:pubmed |
| pubmed-article:8683378 | pubmed:author | pubmed-author:YamamotoAA | lld:pubmed |
| pubmed-article:8683378 | pubmed:author | pubmed-author:YamashitaMM | lld:pubmed |
| pubmed-article:8683378 | pubmed:author | pubmed-author:OhtsukiYY | lld:pubmed |
| pubmed-article:8683378 | pubmed:author | pubmed-author:KuwaharaMM | lld:pubmed |
| pubmed-article:8683378 | pubmed:author | pubmed-author:SonobeHH | lld:pubmed |
| pubmed-article:8683378 | pubmed:author | pubmed-author:TeraoNN | lld:pubmed |
| pubmed-article:8683378 | pubmed:author | pubmed-author:MoriokaMM | lld:pubmed |
| pubmed-article:8683378 | pubmed:author | pubmed-author:FurihataMM | lld:pubmed |
| pubmed-article:8683378 | pubmed:author | pubmed-author:FujisakiNN | lld:pubmed |
| pubmed-article:8683378 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8683378 | pubmed:volume | 178 | lld:pubmed |
| pubmed-article:8683378 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8683378 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8683378 | pubmed:pagination | 133-9 | lld:pubmed |
| pubmed-article:8683378 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:meshHeading | pubmed-meshheading:8683378-... | lld:pubmed |
| pubmed-article:8683378 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8683378 | pubmed:articleTitle | Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. | lld:pubmed |
| pubmed-article:8683378 | pubmed:affiliation | Department of Pathology II, Kochi Medical School, Nankoku, Japan. | lld:pubmed |
| pubmed-article:8683378 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8683378 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8683378 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8683378 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8683378 | lld:pubmed |
